{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:18:22Z","timestamp":1792081102243,"version":"4.4.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01289-7","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T15:33:41Z","timestamp":1745854421000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Revised free light chain reference intervals enhance risk stratification in monoclonal gammopathy of undetermined significance and reduce overdiagnosis"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7205-9330","authenticated-orcid":false,"given":"Cecilie Velsoe","family":"Maeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e6mundur","family":"R\u00f6gnvaldsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2377-7886","authenticated-orcid":false,"given":"Th\u00f3rir","family":"Einarsson Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1816-8106","authenticated-orcid":false,"given":"Christian","family":"Brieghel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1754-5336","authenticated-orcid":false,"given":"Emil","family":"Hermansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9880-5242","authenticated-orcid":false,"given":"Carsten Utoft","family":"Niemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Gr\u00f8nb\u00e6k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4964-7476","authenticated-orcid":false,"given":"Sigur\u00f0ur Yngvi","family":"Kristinsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5017-3530","authenticated-orcid":false,"given":"Sigr\u00fan","family":"Thorsteinsd\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"1289_CR1","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1056\/NEJMoa01133202","volume":"346","author":"RA Kyle","year":"2002","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564\u20139.","journal-title":"N Engl J Med"},{"key":"1289_CR2","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.3324\/haematol.2023.283191","volume":"108","author":"A\u00dd Sigurbergsd\u00f3ttir","year":"2023","unstructured":"Sigurbergsd\u00f3ttir A\u00dd, R\u00f6gnvaldsson S, Thorsteinsd\u00f3ttir S, Sverrisd\u00f3ttir I, Sigur\u00f0ard\u00f3ttir G\u00c1, Vi\u00f0arsson B, et al. Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: results from the population-based iStopMM study. Haematologica. 2023;108:3392\u20138.","journal-title":"Haematologica"},{"key":"1289_CR3","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","volume":"113","author":"O Landgren","year":"2009","unstructured":"Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113:5412\u20137.","journal-title":"Blood"},{"key":"1289_CR4","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.62347\/VFDM5811","volume":"14","author":"H Xu","year":"2024","unstructured":"Xu H, Tian J, Li L, Liu F, Ren Y, Guo G, et al. Risk factors for the outcome and prognosis of multiple myeloma patients with pathological fractures undergoing percutaneous vertebroplasty. Am J Cancer Res. 2024;14:2946\u201356.","journal-title":"Am J Cancer Res"},{"key":"1289_CR5","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1093\/ndt\/gfz211","volume":"36","author":"M Courant","year":"2021","unstructured":"Courant M, Orazio S, Monnereau A, Preterre J, Combe C, Rigothier C. Incidence, prognostic impact and clinical outcomes of renal impairment in patients with multiple myeloma: a population-based registry. Nephrol Dial Transplant. 2021;36:482\u201390.","journal-title":"Nephrol Dial Transplant"},{"key":"1289_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12706-8","volume":"24","author":"LA Rasmussen","year":"2024","unstructured":"Rasmussen LA, Vedsted P, Jensen H, Frederiksen H, El-Galaly TC, Kristensen IB, et al. Multiple myeloma: unplanned diagnostic pathways and association with risk factors and survival - a nationwide register-based cohort study in Denmark. BMC Cancer. 2024;24:998.","journal-title":"BMC Cancer"},{"key":"1289_CR7","unstructured":"Danish Myeloma Study Group (DMSG). MGUS\u2014udredning og opf\u00f8lgning af monoklonal gammopati med ubestemt signifikans. (2025)."},{"key":"1289_CR8","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Kyle RA, Buadi FK. Advances in the Diagnosis, Classification, Risk Stratification, and Management of Monoclonal Gammopathy of Undetermined Significance: Implications for Recategorizing Disease Entities in the Presence of Evolving Scientific Evidence. 10th ed. Mayo Clinic Proceedings, editor. Vol. 85. 945\u20138 p. (2010).","DOI":"10.4065\/mcp.2010.0520"},{"key":"1289_CR9","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","volume":"106","author":"SV Rajkumar","year":"2005","unstructured":"Rajkumar SV, Kyle RA, Therneau TM, Melton LJ, Bradwell AR, Clark RJ, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106:812\u20137.","journal-title":"Blood"},{"key":"1289_CR10","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s10238-024-01471-4","volume":"24","author":"D Shpitzer","year":"2024","unstructured":"Shpitzer D, Cohen YC, Perry C, Melamed G, Alapi H, Reiner-Benaim A, et al. Clinical significance of FLC tests in patients without other evidence of hematologic disorder. Clin Exp Med. 2024;24:198.","journal-title":"Clin Exp Med"},{"key":"1289_CR11","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/clinchem\/48.9.1437","volume":"48","author":"JA Katzmann","year":"2002","unstructured":"Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48:1437\u201344.","journal-title":"Clin Chem"},{"key":"1289_CR12","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.2215\/CJN.02290508","volume":"3","author":"CA Hutchison","year":"2008","unstructured":"Hutchison CA, Harding S, Hewins P, Mead GP, Townsend J, Bradwell AR, et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008;3:1684\u201390.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1289_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00732-3","volume":"12","author":"TE Long","year":"2022","unstructured":"Long TE, Indridason OS, Palsson R, Rognvaldsson S, Love TJ, Thorsteinsdottir S, et al. Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study. Blood Cancer J. 2022;12:133.","journal-title":"Blood Cancer J"},{"key":"1289_CR14","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1182\/blood-2023-188547","volume":"142","author":"T Einarsson Long","year":"2023","unstructured":"Einarsson Long T, R\u00f6gnvaldsson S, Thorsteinsdottir S, Sverrisdottir I, Eythorsson E, Indridason O, et al. Revised definition of free light chains in serum and light chain monoclonal gammopathy of undetermined significance: results of the istopmm study. Blood. 2023;142:535.","journal-title":"Blood"},{"key":"1289_CR15","doi-asserted-by":"crossref","unstructured":"Shpitzer D, Cohen YC, Shragai T, Melamed G, Reiner-Benaim A, Avivi I. Adopting the new iStopMM-based criteria for light-chain monoclonal gammopathy of undetermined significance: an ongoing debate. Haematologica. 2024.","DOI":"10.3324\/haematol.2024.286239"},{"key":"1289_CR16","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1093\/jnci\/djq099","volume":"102","author":"HG Welch","year":"2010","unstructured":"Welch HG, Black WC. Overdiagnosis in Cancer. JNCI J Natl Cancer Inst. 2010;102:605\u201313.","journal-title":"JNCI J Natl Cancer Inst"},{"key":"1289_CR17","doi-asserted-by":"crossref","unstructured":"Brieghel C, Werling M, Frederiksen CM, Parviz M, Lacoppidan T, Faitova T, et al. The Danish Lymphoid Cancer Research (DALY-CARE) Data Resource: The Basis for Developing Data-Driven Hematology. Clin Epidemiol. 2025.","DOI":"10.1101\/2024.04.11.24305663"},{"key":"1289_CR18","doi-asserted-by":"publisher","first-page":"570","DOI":"10.32614\/RJ-2021-053","volume":"13","author":"DD Sjoberg","year":"2021","unstructured":"Sjoberg DD, Whiting K, Curry M, Lavery JA, Larmarange J. Reproducible Summary Tables with the gtsummary Package. R J. 2021;13:570.","journal-title":"R J"},{"key":"1289_CR19","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.21105\/joss.01686","volume":"4","author":"H Wickham","year":"2019","unstructured":"Wickham H, Averick M, Bryan J, Chang W, McGowan L, Fran\u00e7ois R, et al. Welcome to the Tidyverse. J Open Source Softw. 2019;4:1686.","journal-title":"J Open Source Softw"},{"key":"1289_CR20","doi-asserted-by":"crossref","unstructured":"Holst KK mets: Analysis of Multivariate Event Times. CRAN: Contributed Packages. 2012.","DOI":"10.32614\/CRAN.package.mets"},{"key":"1289_CR21","doi-asserted-by":"crossref","unstructured":"Harrell FE Jr. rms: Regression Modeling Strategies. CRAN: Contributed Packages. 2009.","DOI":"10.32614\/CRAN.package.rms"},{"key":"1289_CR22","unstructured":"prodlim: Product-Limit Estimation for Censored Event History Analysis. CRAN: Contributed Packages. 2008."},{"key":"1289_CR23","doi-asserted-by":"crossref","unstructured":"Therneau TM. survival: Survival Analysis. CRAN: Contributed Packages. 2001.","DOI":"10.32614\/CRAN.package.survival"},{"key":"1289_CR24","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/leu.2010.60","volume":"24","author":"RA Kyle","year":"2010","unstructured":"Kyle RA, Durie BGM, Rajkumar SV, Landgren O, Blade J, Merlini G, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24:1121\u20137.","journal-title":"Leukemia"},{"key":"1289_CR25","unstructured":"Dansk Myelomatose Studie Gruppe (DMSG). Diagnostik og opf\u00f8lgning af MGUS\u2014Retningslinje 2018. 2018."},{"key":"1289_CR26","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/leu.2008.307","volume":"23","author":"A Dispenzieri","year":"2009","unstructured":"Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009;23:215\u201324.","journal-title":"Leukemia"},{"key":"1289_CR27","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1182\/blood-2003-03-0801","volume":"102","author":"RA Kyle","year":"2003","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Remstein ED, Offord JR, Larson DR, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood. 2003;102:3759\u201364.","journal-title":"Blood"},{"key":"1289_CR28","doi-asserted-by":"publisher","first-page":"4136","DOI":"10.1182\/blood.V116.21.4136.4136","volume":"116","author":"MJ Maurer","year":"2010","unstructured":"Maurer MJ, Cerhan J, Katzmann JA, Link B, Micallef IN, Colgan J, et al. Elevation of serum free light chains are common in lymphoma and associated with poor event free and overall survival. Blood. 2010;116:4136.","journal-title":"Blood"},{"key":"1289_CR29","doi-asserted-by":"publisher","first-page":"854","DOI":"10.3324\/haematol.2011.054015","volume":"97","author":"SY Kristinsson","year":"2012","unstructured":"Kristinsson SY, Tang M, Pfeiffer RM, Bjorkholm M, Goldin LR, Blimark C, et al. Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. Haematologica. 2012;97:854\u20138.","journal-title":"Haematologica"},{"key":"1289_CR30","doi-asserted-by":"publisher","first-page":"431","DOI":"10.11613\/BM.2021.030701","volume":"31","author":"M Daves","year":"2021","unstructured":"Daves M, Piccin A, Roccaforte V, Lippi G. Comparison of Freelite and N-Latex serum free light chain assays. Biochem Med (Zagreb). 2021;31:431\u20138.","journal-title":"Biochem Med (Zagreb)"}],"updated-by":[{"DOI":"10.1038\/s41408-025-01307-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000}}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01289-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01289-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01289-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T06:01:22Z","timestamp":1748412082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01289-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1289"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01289-7","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"assertion":[{"value":"14 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: Tab. 3 has been updated has been updated due to an incorrect formatting occurred during the correction process.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41408-025-01307-8","URL":"https:\/\/doi.org\/10.1038\/s41408-025-01307-8","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CVM has participated in a conference supported by Daiichi Sankyo. SR has received honoraria for scientific talks from Siemens Healthineers and Johnson & Johnson. TL has no conflicts of interest to declare. CB has received an honorarium from AbbVie. EH reports honoraria for lectures and educational materials from Amgen, Bristol Myers Squibb, Johnson & Johnson, Pfizer, Sanofi, and Takeda, research cooperation with Bristol Myers Squibb, Johnson & Johnson, and Sanofi, participation in conferences supported by Bristol Myers Squibb, Pfizer, Roche, and Takeda, and advisory board consultancy to Johnson & Johnson, Sanofi, and Oncopeptides. CUN has received research funding from AbbVie, Johnson & Johnson, AstraZeneca, Novo Nordisk Foundation, Genmab, and Octapharma, and has provided consultancy for AbbVie, BeiGene, Janssen, Roche, AstraZeneca, CSL Behring, Genmab, Takeda, Octapharma, MSD, Synamics, and Lilly. KG has received research funding from Janssen. SYK reports research funding from Amgen and Celgene, and an Independent Data Monitoring Committee for Johnson & Johnson. ST has received honoraria for scientific talks from AbbVie and Thermo Fisher Scientific.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted under the approval of Danish Lymphoid Cancer Research (DALYCARE) protocol by the Danish National Ethics Committee (1804410) and Data Protection Agency (P-2020-561). All methods were performed in compliance with all relevant guidelines and regulations for use of Danish data, including legal exemption from informed consent as a nationwide epidemiological study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"80"}}